Gender-based personalized pharmacotherapy: a systematic review

Archives of Gynecology and Obstetrics

Volumn 295, Issue 6, 2017, Pages 1305-1317

  Islam, Md Mohaimenul ^a   Nguyen, Phung Anh ^a   Poly, Tahmina Nasrin ^c  

^a Jack)   (Taiwan)

^b Jack)   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Adverse effect; Drug interaction; Gender based; Pharmacokinetics; Pharmacotherapy

Indexed keywords

BODY WEIGHT; DOSE CALCULATION; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; MALE; PERSONALIZED MEDICINE; PHARMACOKINETICS; PROCEDURES; SEX DIFFERENCE; STOMACH EMPTYING;

BODY WEIGHT; DRUG DOSAGE CALCULATIONS; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; HUMANS; MALE; PHARMACOKINETICS; PRECISION MEDICINE; SEX FACTORS;

EID: 85027885312     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-017-4363-3     Document Type: Review

References (99)

1. Harris RZ, Benet LZ, Schwartz JB (1995) Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50(2):222–239
2. Rowland M, Tozer T (1989) Assessment of area. In: Clinical pharmacokinetics: concepts and applications (2nd edn). Lea & Febiger, Philadelphia, pp 459–463
3. Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP (2010) Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. J Clin Pharmacol 50(12):1358–1366
4. Cheymol G (1993) Clinical pharmacokinetics of drugs in obesity. Clin Pharmacokinet 25(2):103–114
5. Greenblatt DJ, Friedman H, Burstein ES, Scavone JM, Blyden GT, Ochs HR, Miller LG, Harmatz JS, Shader RI (1987) Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 42(2):193–200
6. Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ (1991) Pharmacokinetics of sufentanil in obese patients. Anesthesia Analgesia 73 (6):790–793
7. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, Ferry JJ, Jusko WJ (1993) Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54(4):402
8. Ensom MH (2000) Gender-based differences and menstrual cycle-related changes in specific diseases: implications for pharmacotherapy. Pharmacother J Hum Pharmacol Drug Ther 20(5):523–539
9. Koren G (2010) Is it appropriate to study the pharmacokinetics of drugs aimed at pregnant women in men? J Obstet Gynaecol Can 32(7):629–630
10. Schwartz JB, Capili H, Daugherty J (1994) Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 55(5):509–517
11. Anderson GD (2008) Gender differences in pharmacological response. Int Rev Neurobiol 83:1–10
12. Magee MH, Blum RA, Lates CD, Jusko WJ (2001) Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 41(11):1180–1194
13. Freedman RR, Sabharwal SC, Desai N (1987) Sex differences in peripheral vascular adrenergic receptors. Circ Res 61(4):581–585
14. Walker JS, Carmody JJ (1998) Experimental pain in healthy human subjects: gender differences in nociception and in response to ibuprofen. Anesthesia Analgesia 86 (6):1257–1262
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341
16. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD (2009) Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 81(5):747–753
17. Ibarra M, Vázquez M, Fagiolino P, Derendorf H (2013) Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn 40(4):479–486
18. Nichols A, Richards L, Behrle J, Posener J, Fruncillo R (2013) Effects of age and sex on the pharmacokinetics, safety, and tolerability of oral desvenlafaxine in healthy adults. J Bioequiv Availab 5:088–094
19. Abbas M, Khan AM, Riffat S, Tipu MY, Nawaz HA, Usman M (2014) Assessment of sex differences in pharmacokinetics of carvedilol in human. Pak J Pharm Sci 27(5):1265–1269
20. Zulfiqar-ul-Hassan SR, Naseer R (2008) Gender differences on bioavailabity of ofloxacin. J Ayub Med Coll Abbottabad 20(2):114–117
21. Barbier AJ, Hilhorst M, Van Vliet A, Snyder P, Palfreyman MG, Gawryl M, Dgetluck N, Massaro M, Tiessen R, Timmerman W (2015) Pharmacodynamics, pharmacokinetics, safety, and tolerability of encenicline, a selective α 7 nicotinic receptor partial agonist, in single ascending-dose and bioavailability studies. Clin Ther 37(2):311–324
22. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P (2003) Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 160(9):1643–1650
23. Essebag V, Reynolds MR, Hadjis T, Lemery R, Olshansky B, Buxton AE, Josephson ME, Zimetbaum P (2007) Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med 167(15):1648–1653
24. La Porte C, Burger D, Gyssens I, Sprenger H, Koopmans P (2003) Gender differences in nevirapine pharmacokinetics, fact or fiction. In: Fourth international workshop on clinical pharmacology of HIV therapy, pp 27–29
25. Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischi M, DiFrancesco R, Morse GD (2005) Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet 44(1):99–109
26. Ofotokun I, Chuck SK, Hitti JE (2007) Antiretroviral pharmacokinetic profile: a review of sex differences. Gender Med 4(2):106–119
27. Pai MP, Schriever CA, Diaz-Linares M, Novak RM, Rodvold KA (2004) Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacother J Hum Pharmacol Drug Ther 24(5):592–599
28. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM (2004) Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 189(7):1176–1184
29. Besi E, Boniface D, Cregg R, Zakrzewska J (2015) Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain 16(1):1
30. Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ (1999) Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66(6):594–601
31. Johnson JA, Akers WS, Herring VL, Wolfe MS, Sullivan JM (2000) Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacother J Hum Pharmacol Drug Ther 20(6):622–628
32. Härtter S, Wetzel H, Hammes E, Hiemke C (1993) Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 110(3):302–308
33. Abuelkheir MM (2009) Effect of pharmacokinetic differences between men and women on pharmacodynamic target attainment of levofloxacin against streptococcus pneumoniae. Saudi Pharm J 17(1):29–39
34. Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD (2014) Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother 69(12):3300–3310
35. Sargent S, Green S, Para M (1998) Sustained plasma viral burden reductions and CD4 increases in HIV-1 infected patients with RESCRIPTOR (DLV) + RETROVIR (ZDV) + EPIVIR (3TC). In: From: 5th conference on retroviruses and opportunistic infections
36. Csajka C, Marzolini C, Fattinger K, Décosterd LA, Telenti A, Biollaz J, Buclin T (2004) Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 48(9):3226–3232
37. Vazquez B, Yang H, Williams B, Zhou S, Laurenza A (2015) Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia 56(7):e90–e94
38. Macpherson M, Hamrén B, Braamskamp MJ, Kastelein JJ, Lundström T, Martin PD (2016) Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia. Eur J Clin Pharmacol 72(1):19–27
39. Kang D, Verotta D, Krecic-Shepard ME, Modi NB, Gupta SK, Schwartz JB (2003) Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther St Louis 73 (1):31–40
40. Mohamed MH, Lima JJ, Eberle LV, Self TH, Johnson JA (1999) Effects of gender and race on albuterol pharmacokinetics. Pharmacother J Hum Pharmacol Drug Ther 19(2):157–161
41. Xue F, Liao X, Liu J, Tong S, Zhang Y, Zhang R, An G, Luo L (1998) Dose-response curve and time-course of effect of vecuronium in male and female patients. Br J Anaesth 80(6):720–724
42. Hildebrandt MG, Steyerberg EW, Stage KB, Passchier J, Kragh-Soerensen P, Group DUA (2003) Are gender differences important for the clinical effects of antidepressants? Am J Psychiatry 160(9):1643–1650
43. Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T (1999) Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). JAIDS J Acquir Immune Defic Syndr 21(4):281–292
44. Besi E, Boniface D, Cregg R, Zakrzewska J (2015) Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). J Headache Pain 16(1):1–7
45. Milesi-Hallé A, Hambuchen MD, McMillan DE, Owens SM (2015) The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug Alcohol Depend 150:164–169
46. Nazir S, Iqbal Z, Shah Y, Ahmad L, Khan A (2015) Pharmacokinetic study of rosuvastatin in males and females. Eur J Drug Metab Pharmacokinet 40(3):313–318
47. Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I (2004) Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 48(11):4256–4262
48. Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329–342
49. del Carrasco-Portugal MC, Flores-Murrieta FJ (2011) Gender differences in the pharmacokinetics of oral drugs. Pharmacol Pharmacy 2 (01):31
50. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523
51. Coşkun J, Sevinc A, Tevetoğlu I, Alican I, Kurtel H, Yeğen B (1995) Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Res Exp Med 195(1):49–54
52. Anderson GD (2005) Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Women’s Health 14(1):19–29
53. Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42(2):107–121
54. Overholser BR, Kays MB, Forrest A, Sowinski KM (2004) Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 44(9):1012–1022
55. Sowinski KM, Abel SR, Clark WR, Mueller BA (1999) Effect of gender on the pharmacokinetics of ofloxacin. Pharmacother J Hum Pharmacol Drug Ther 19(4):442–446
56. Chien S, Chow A, Natarajan J, Williams R, Wong F, Rogge M, Nayak R (1997) Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41(7):1562–1565
57. Efthymiopoulos C, Bramer SL, Maroli A (1997) Effect of age and gender on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 33(1):9–17
58. Zhang X, Overholser BR, Kays MB, Sowinski KM (2006) Gatifloxacin pharmacokinetics in healthy men and women. J Clin Pharmacol 46(10):1154–1162
59. Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37(11):529–547
60. Pleym H, Spigset O, Kharasch E, Dale O (2003) Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiologica Scandinavica 47(3):241–259
61. Tie H-T, Xia Y-Y, Zeng Y-S, Zhang Y, Dai C-L, Guo JJ, Zhao Y (2014) Risk of childhood overweight or obesity associated with excessive weight gain during pregnancy: a meta-analysis. Arch Gynecol Obstet 289(2):247–257
62. Custodio JM, Wu C-Y, Benet LZ (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60(6):717–733
63. Pérez JF, Olguín HJ, Pérez CF, Guillé GP, Pérez AG, Vieyra AC, López AT, Portugal MC, Asseff IL (2003) Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int 20(3):499–508
64. Alomar MJ (2014) Factors affecting the development of adverse drug reactions (review article). Saudi Pharma J 22(2):83–94
65. Arthur M, Lee A, Wright R (1984) Sex differences in the metabolism of ethanol and acetaldehyde in normal subjects. Clin Sci 67(4):397–401
66. Kristjansson F, Thorsteinsson S (1990) Disposition of alprazolam in human volunteers. Differences between genders. Acta pharmaceutica nordica 3(4):249–250
67. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A (1991) Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 50(4):404–409
68. Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, Kuranari M, Miyakawa I, Nakano S (2001) The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 70(2):121–125
69. Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50(5–1):508–519
70. Bock KW, Schrenk D, Forster A, Griese E-U, Mörike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharm Genom 4(4):209–218
71. Relling MV, Lin Js, Ayers GD, Evans WE (1992) Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities. Clin Pharmacol Ther 52(6):643–658
72. Ou-Yang DS, Huang SL, Wang W, Xie HG, Xu ZH, Shu Y, Zhou HH (2000) Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49(2):145–151
73. Miners J, Attwood J, Birkett D (1983) Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16(5):503–509
74. Kaye CM, Nicholls B (2000) Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39(4):243–254
75. Shah AK, LaBoy-Goral M, Scott N, Morse M, Apseloff G (2001) Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 41(12):1339–1344
76. Pouyanne P, Haramburu F, Imbs JL, Bégaud B (2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. Bmj 320(7241):1036
77. Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL (2000) Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 49(2):158–167
78. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD (1998) Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 46(5):505–511
79. Figueras A, Capella D, Castel J, Laporte J (1994) Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 47(4):297–303
80. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH (1993) Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. Jama 270(21):2590–2597
81. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A (2002) Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol 16 (5):343–346
82. Klein U, Klein M, Sturm H, Rothenbühler M, Huber R, Stucki P, Gikalov I, Keller M, Hoigne R (1976) The frequency of adverse drug reactions as dependent upon age, sex and duration of hospitalization. International journal of clinical pharmacology biopharmacy 13(3):187–195
83. Domecq C, Naranjo C, Ruiz I, Busto U (1979) Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 18(8):362–366
84. Tran C, Knowles SR, Liu BA, Shear NH (1998) Gender differences in adverse drug reactions. J Clin Pharmacol 38(11):1003–1009
85. Dressler N, Chandra A, Dávila LA, Spineli L, Schippert C, von Versen-Höynck F (2016) BMI and season are associated with vitamin D deficiency in women with impaired fertility: a two-centre analysis. Arch Gynecol Obstet 293(4):907–914
86. Mattisson D (2008) Sex differences in drug development. Blickpunkt der Mann 6 (1):21–25
87. Kando JC, Yonkers KA, Cole JO (1995) Gender as a risk factor for adverse events to medications. Drugs 50(1):1–6
88. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3 A substrates. Clin Pharmacokinet 44(1):33–60
89. Ducharme MP, Slaughter RL, Edwards DJ (1994) Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 16(5):513–518
90. Bauer J, Groneberg DA, Brueggmann D (2016) Gender-based workplace assessment in gynecology and obstetrics in Germany: results from the iCEPT Study. Arch Gynecol Obstet 294(2):317–326
91. Hwang A, Chou L, Islam M, Li Y-C, Syed-Abdul S (2016) Risk factors for ectopic pregnancy in the Taiwanese population: a retrospective observational study. Arch Gynecol Obstet 294(4):779–783
92. Islam MM, Iqbal U, Walther B, Atique S, Dubey N, Nguyen P-A, Poly T, Masud J, Li Y-C, Shabbir S-A (2016) Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology 47(3–4):181–191
93. Borgelt LM (2010) Women’s health across the lifespan: a pharmacotherapeutic approach. Can J Hosp Pharm 64(2):153
94. Hirose A, Terauchi M, Akiyoshi M, Owa Y, Kato K, Kubota T (2016) Low-dose isoflavone aglycone alleviates psychological symptoms of menopause in Japanese women: a randomized, double-blind, placebo-controlled study. Arch Gynecol Obstet 293(3):609–615
95. Nicolson TJ, Mellor HR, Roberts RR (2010) Gender differences in drug toxicity. Trends Pharmacol Sci 31(3):108–114
96. Wood AJ, Zhou HH (1991) Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 20(5):350–373
97. Tornatore KM, Reed KA, Venuto RC (1993) Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacother J Hum Pharmacol Drug Ther 13(5):481–486
98. Tornatore KM, Biocevich DM, Reed K, Tousley K, Singh JP, Venuto RC (1995) Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation 59(5):729–736
99. Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. ClinPharmacokinet 48(3):143–157